Dr. Abbey Participated in Roundtable Discussion on Newer Therapies for Wet AMD and Diabetic Macular Edema
Texas Retina’s Ashkan Abbey, MD, recently participated in a roundtable discussion on “Navigating Wet AMD and DME Using Newer Therapies” available on Eyetube. Dr. Abbey and fellow panelist Scott Walter, MD, MSc,
read more
Offices Closed for Labor Day on 9/2/24
All Texas Retina Associates offices will be closed on Monday, September 2, 2024, in observance of Labor Day. We wish everyone a safe and happy holiday weekend!
read more
Dr. Abbey Discusses Cataract Surgery in Patients with AMD on New Podcast Episode
Cataracts and age-related macular degeneration (AMD) are two of the most common eye conditions. Texas Retina’s Ashkan Abbey, MD, was recently invited to participate in the latest episode of “Blind Spot –
read more
Dr. Abbey Publishes Case Report on Management of Cystoid Macular Edema in Coats’ Disease
Texas Retina’s Ashkan M. Abbey, MD, recently co-authored a case report in the medical journal Ophthalmic Surgery, Lasers and Imaging Retina (OSLI Retina) on the use of an injectable flucocinolone implant for
read more
Can Ozempic Affect Your Eyes or Vision?
Initially approved by the U.S. Food and Drug Administration (FDA) to help control blood sugar and treat type 2 diabetes, semaglutide (brand names Ozempic, Wegovy and Rybelsus) has also emerged as a
read more
Recent Study Published in Journal of Clinical Oncology Highlights Importance of Prognostic Biomarker for Uveal Melanoma
The results of the Collaborative Ocular Oncology Study Number 2 (COOG2) were published in the July 2024 issue of the Journal of Clinical Oncology and validated the prognostic accuracy of the integrated
read more Dr. Abbey First in the World to Administer Novel Trispecific Fusion Antibody EB-105 for Diabetic Macular Edema as Part of Phase Ib LOTUS Clinical Trial
On July 9, Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, dosed the first patient in the Phase Ib LOTUS trial of EB-105, the world’s first pentavalent trispecific
read more
Dr. Anand Presented Interim Study Results of New Gene Therapy for X-linked Retinitis Pigmentosa at ASRS 2024 Annual Meeting
Texas Retina’s Rajiv Anand, MD, presented “Subretinal AGTC-501 Gene Therapy for XLRP: 12-Month Interim Safety & Efficacy Results of the Randomized Controlled Multicenter Phase II Skyline Trial” at the 2024 Annual Meeting
read more
July is UV Safety Month — Debunking Seven Common Myths About Sunglasses
When most people think of UV protection, they think of their skin and sunscreen. Did you know that long-term exposure to bright sunlight may also increase your risk of eye disease? July
read more Dr. Abbey Presents GALE Study Data at the Association for Research in Vision and Ophthalmology
At this year’s ARVO 2024, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), Texas Retina’s Dr. Abbey presented 36-month data from the GALE study of pegcetacoplan (brand
read more